Results 171 to 180 of about 175,837 (263)

Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial. [PDF]

MedComm (2020)
Lin J, Chen L, Chen L, Wang D, Lu Y, Zhang H, Chen P, Yan W, Xiao Z, Chen Y.   +9 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Recent Advances in the Treatment of Melanoma

Cancer Control, 2013
Jonathan S, Zager, Amod A, Sarnaik, Geoffrey T, Gibney, Ragini R, Kudchadkar   +3 more
openaire   +2 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

GLUT1 expression, lymphocyte distribution and CD3⁺ T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma. [PDF]

J Exp Clin Cancer Res
Paver EC, Gide TN, Yaseen Z, Cornejo-Paramo P, Ferguson P, Maher NG, Menzies AM, Carlino MS, da Silva IP, Holst J, Long GV, Scolyer RA, Wilmott JS.   +12 more
europepmc   +1 more source

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

BMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jing‐Yi Zhu, Wei Xue   +6 more
wiley   +1 more source

Current Treatment Paradigms for Advanced Melanoma with Brain Metastases. [PDF]

Int J Mol Sci
Bonzano E, Barruscotti S, Chiellino S, Montagna B, Bonzano C, Imarisio I, Colombo S, Guerrini F, Saddi J, La Mattina S, Tomasini CF, Spena G, Pedrazzoli P, Lancia A.   +13 more
europepmc   +1 more source

Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy

Chemistry – A European Journal, EarlyView.
Integrin αVβ3‐targeting small‐molecule drug conjugates (SMDCs) were synthesized by conjugating a cryptophycin payload through a neutrophil elastase‐cleavable NPV‐PABC linker. RGD peptidomimetic and linker epimers served as controls for targeting and enzymatic cleavage, and the resulting conjugates displayed subnanomolar cytotoxicity in vitro.
Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald   +3 more
wiley   +1 more source

Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.

Acta Derm Venereol
Goller S, Dege T, Schummer P, Haug L, Meir M, Gehrke T, Klein D, Goebeler M, Kneitz H, Schilling B, Gesierich A, Glutsch V.   +11 more
europepmc   +1 more source